Advancell initiates ATH008 phase IIb study for hand-foot syndrome

[News]

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

More... (http://www.news-medical.net/news/20110420/Advancell-initiates-ATH008-phase-IIb-study-for-hand-foot-syndrome.aspx)